CD8A and neoplasm: These results suggest that SCD1 inhibition acts directly on tumor cells to enhance the production of CCL4 via the β-catenin/ATF3 axis, which results in the enhanced recruitment of DCs into tumors and the subsequent CD8+ T cell induction and accumulation.